Flexible Dosing for Adults
Open Arrow Close ArrowExplore KEYTRUDA® dosing options
Flexible dosing options for your adult patients
KEYTRUDA® offers two dosing regimens that allow you to decide which dosing frequency is most appropriate for your adult patients.
Q3W |
Q6W |
200 mg |
400 mg |
Approximately 17 infusions/year
|
Approximately 8 infusions/year
|
|
|
Patients should be treated with KEYTRUDA® until disease progression, unacceptable toxicity or the pre-defined duration in the Product Monograph. Duration of treatment varies based on the indication. Please see the KEYTRUDA® Product Monograph for complete dosing information.
|
Dosing by Indication
Go now![Q6W Dosing Trial](https://keytruda-ca.rakecdn.net/uploads/2023/03/subhead2-copy-2@2x.png)
Q6W Dosing Trial
Open Arrow Close ArrowTrial KEYNOTE-555:
In KEYNOTE-555, 44 patients with advanced melanoma received KEYTRUDA® monotherapy at a dose of 400 mg every 6 weeks. Based on observed preliminary pharmacokinetic and clinical data from an interim analysis of KEYNOTE-555, no clinically significant differences in efficacy and safety are expected between KEYTRUDA® doses of 200 mg or 2 mg/kg every 3 weeks or 400 mg every 6 weeks.
In peripheral blood of patients who received KEYTRUDA® 2 mg/kg every 3 weeks or 10 mg/kg every 2 weeks or 3 weeks, an increased percentage of activated (i.e., HLA-DR+) CD4+ and CD8+ T-cells was observed after treatment, at all doses and schedules, without an increase in the circulating T-lymphocyte number.
KEYNOTE-555: Alternate Dosing Regimen for Adults
The safety and efficacy of KEYTRUDA® 400 mg every 6 weeks was evaluated in Cohort B of KEYNOTE-555, was a Phase 1 clinical trial in adult patients with advanced (unresectable or metastatic) melanoma (at least 1 measurable lesion) who were naïve to prior immuno oncology therapy, and had an ECOG performance status of 0 or 1. The interim data of 44 patients support that the safety and efficacy of 400 mg every 6 weeks are consistent with the safety and efficacy of 200 mg every 3 weeks of KEYTRUDA®.